Skip to content
Buy This GLP
← Research
Formats

Can a Lower Tirzepatide Dose Help Maintain Weight Loss?

In SURMOUNT-MAINTAIN, weight at week 112 was 16.6% below baseline on 5 mg tirzepatide, 21.9% below on the maximum tolerated dose and 9.9% below on placebo.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team8 min read
What sits between the two answers people are offeredcontinue at full dosemonitored dose reductionreduced-frequency dosingswitch to the oralintermittent rescuestructured lifestyle supportstopA randomized trial compared continuation, dose reduction and stopping.

In SURMOUNT-MAINTAIN, adults who switched to 5 mg of tirzepatide maintained more of their weight loss than those who switched to placebo. After 60 weeks on tirzepatide, 378 adults were randomized three ways for another 52 weeks [2]. Continue at the maximum tolerated dose, drop to 5 mg, or switch to placebo. At week 112, weight sat 21.9% below baseline on the full dose, 16.6% at 5 mg and 9.9% on placebo.

In the trial’s comparison of rescue treatment, 11 of 138 participants (8%) in the maximum-tolerated-dose group received rescue tirzepatide, compared with 35 of 142 (25%) in the 5 mg group and 60 of 90 (67%) in the placebo group[2]. The trial allowed rescue after participants regained at least half the weight they had lost.

The research on weight regain after stopping covers what happened across a broader set of studies. SURMOUNT-MAINTAIN instead measured how a specific dose reduction compared with continuing or stopping tirzepatide.

The reframe

Regain after stopping, the authors suggest, may reflect the re-emergence of biological pressures favoring weight restoration rather than a failure of treatment. [1] That is not a semantic move. If regain is the body resuming a defended position, the question is how much ongoing pressure holds the line. That is a dose question, not a yes-or-no one.

They propose the term adaptive maintenance. It means the minimum intensity that preserves meaningful health benefit, weighed against relapse risk, treatment burden and what the patient wants.

What is established and what is not

Continued obesity medication has the strongest direct evidence for limiting regain[1]. The long-term safety guide covers what multi-year trials reported about adverse events during continued treatment. SURMOUNT-MAINTAIN provides randomized evidence for a particular reduction in tirzepatide dose among adults who reached randomization after the initial treatment period [2].

The narrative perspective also discusses switching to an oral formulation, spacing doses, intermittent rescue therapy and structured lifestyle support [1]. The review of weight regain after stopping treatment summarizes withdrawal trials. The lower-dose tirzepatide trial tested a different approach.

Monitoring during maintenance

The narrative perspective suggests tracking changes in hunger, fullness, weight, waist size and metabolic measures during maintenance [1]. These are proposed warning signs. The authors call for studies to test whether tracking them improves outcomes.

Questions to discuss with your prescriber

Ask what outcomes the prescriber would monitor and when you would review the plan together. The GLP-1 price check can help you compare the costs of plans your prescriber considers appropriate. Ask each provider whether its price changes with the prescribed dose.

Frequently asked

Can I just take a lower dose to maintain?
In SURMOUNT-MAINTAIN, participants assigned to 5 mg tirzepatide retained more weight loss than those assigned to placebo and less than those who continued at their maximum tolerated dose. Discuss any change with your prescriber.
Does everybody need to stay on it forever?
No. The authors note that maintenance requirements vary substantially and that some people maintain clinically meaningful weight reduction without continued medication. Which people, and how to tell in advance, is not established.
What are the alternatives to full-dose continuation?
Monitored dose reduction with predefined criteria for re-escalation, switching to an oral formulation, reduced-frequency dosing, intermittent rescue therapy and structured lifestyle support. The trial tested one tirzepatide dose reduction. The other approaches have different or more limited evidence.
Can early warning signs be tracked?
The paper suggests appetite, satiety, food preoccupation, weight trajectory, waist circumference and cardiometabolic markers might flag relapse early, and says explicitly that this requires prospective validation.

Sources

  1. [1] van Bruggen FH, et al. (2026). Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm Obesity Pillars. PMID 42733607
  2. [2] Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath A (2026). Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre randomised trial The Lancet. PMID 42119587

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Formats